SCHEMBL29764580

SCHEMBL29764580

O=C1NC(=S)S/C1=C\c1c[nH]c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 4/20 0.64
NAT1 P18440 5/20 0.59
CA2 P00918 1/20 0.57
EPHX1 P07099 1/20 0.57
ALDH1A1 P00352 3/20 0.57
MAPT P10636 3/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
RAB9A P51151 2/20 0.57
RECQL P46063 1/20 0.57
MYC P01106 1/20 0.56
MAX P61244 1/20 0.56
GSK3B P49841 1/20 0.54
KDM4E B2RXH2 3/20 0.52
LMNA P02545 2/20 0.52
IDH1 O75874 1/20 0.52
HPGD P15428 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NTRK1 P04629 2/20 0.52
DAPK3 O43293 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL622204 1.00 PIM1 (0.64) PIM1NAT1CA2EPHX1ALDH1A1
SCHEMBL622202 1.00 PIM1 (0.64) PIM1NAT1CA2EPHX1ALDH1A1
SCHEMBL622203 1.00 PIM1 (0.64) PIM1NAT1CA2EPHX1ALDH1A1
SCHEMBL2422392 0.87 MEN1 (0.61) PIM1NAT1ALDH1A1MAPTMEN1
SCHEMBL30343486 0.87 MEN1 (0.61) PIM1NAT1ALDH1A1MAPTMEN1
SCHEMBL1249878 0.87 MEN1 (0.61) PIM1NAT1ALDH1A1MAPTMEN1
SCHEMBL1249881 0.87 MEN1 (0.61) PIM1NAT1ALDH1A1MAPTMEN1
SCHEMBL15312912 0.84 KDM4E (0.55) PIM1ALDH1A1MAPTMEN1KMT2A
SCHEMBL622599 0.84 KDM4E (0.55) PIM1ALDH1A1MAPTMEN1KMT2A
SCHEMBL23600257 0.82 CISD1 (0.58) PIM1NAT1CA2EPHX1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US claimed
CN-114945569-A Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or Tau-protein related diseases comprising same 延世大学校产学协力团 2022-08-26 CN claimed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME MAPT, APP, PRNP PIM1 3071/4885NAT1 1239/4885CA2 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.